As of June 2026 the government has enhanced support for generic medicine shops under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, including plans to raise retailer margins and extend credit periods.
Scale and Reach
- Network Size: Over 19,200 Jan Aushadhi Kendras (JAKs) in 2026, up from 84 functional Kendras in 2014.
- National Savings: Citizens saved over ₹40,000 crore through PMBJP medicines.
- State Concentration: Uttar Pradesh 4,042; Kerala 1,791; Karnataka 1,665; Tamil Nadu 1,591 (2026).
- North East Growth: JAKs increased from 1 in 2014 to 417 in 2026.
- Public Hospitals: Brihanmumbai Municipal Corporation to set up 50 generic shops across civic hospitals, starting with Cooper Hospital.
Cost and Quality Evidence
- Academic Study: Springer Nature (19 June 2026) supports broader use of generics to reduce treatment costs without compromising quality.
- MESH Project: All tested generics met quality criteria; Jan Aushadhi average cost ₹2.40 per tablet vs ₹11.17 for branded alternatives.
Policy and Operational Measures
- Retail Incentives (proposed): Margins to be raised up to 50%; credit period extension from 45 to 75 days (reported as of 9 June 2026).
- Procurement & Testing: Medicines supplied via JAKs procured from WHO‑GMP compliant manufacturers and tested in government‑approved laboratories.
- Prescribing Norms: Centre notified collaboration with states and move to mandate prescribing by generic names (statement dated 27 March 2026).
IASPOINT Booster Facts
- PMBJP: Pradhan Mantri Bhartiya Janaushadhi Pariyojana is the central scheme for affordable generic medicines.
- Quality Standards: WHO‑GMP compliance applied for suppliers to JAKs.
- Testing Infrastructure: Quality assurance performed in government‑approved laboratories.